The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
TherapeuticsMD Pretax Margin % Related Terms
TherapeuticsMD Pretax Margin % Historical Data
* Premium members only.
The historical data trend for TherapeuticsMD's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXMD vs CPHI, RMTI, AYTU: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TherapeuticsMD Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD (TXMD) has a Pretax Margin % of 14.23% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TherapeuticsMD and its competitors. According to the industry distribution chart, TherapeuticsMD ranks #566 out of 952 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is TherapeuticsMD's Pretax Margin % too high?
TherapeuticsMD's current Pretax Margin % is 14.23%. The Drug Manufacturers industry median Pretax Margin % is 7.30. TherapeuticsMD's value of 14.23% is 95.1% above this industry median. Based on the distribution chart, TherapeuticsMD ranks #566 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TherapeuticsMD has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's Pretax Margin % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, TherapeuticsMD ranks #566 out of 952 companies for Pretax Margin %. This places TherapeuticsMD in the lower half of its industry. The industry median Pretax Margin % is 7.30. TherapeuticsMD's value of 14.23% is 95.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TherapeuticsMD's current Pretax Margin % of 14.23% is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TherapeuticsMD and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TherapeuticsMD's current Pretax Margin % is 14.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.07, compared to a current price of $2.24 — trading 8.2% above its estimated fair value. The current Pretax Margin % is 14.23% and 95.1% above the Drug Manufacturers industry median of 7.30. TherapeuticsMD's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current Pretax Margin % is 14.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TherapeuticsMD (TXMD) Overvalued in 2026?
Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued.
The current stock price of $2.24 is trading 8.2% above its estimated GF Value™ of $2.07.
GuruFocus considers TherapeuticsMD to be Fairly Valued.
Key valuation signals for TXMD:
Pretax Margin %: 14.23%
GF Value™: $2.07 vs. price of $2.24 (8.2% above fair value)
Industry Position: 95.1% above the Drug Manufacturers median (#566 of 952)
No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
54GF Score
Get the complete analysis for TXMD
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXMD has been successfully added to your 
